Over-the-Counter Medicines
GnalN-Q Tab.
- Product Category
- Analgesics, Antipyretics & Anti-inflammatory Medicines
- Active Ingredients
- Ibuprofen, caffeine anhydrous, allyl isopropyl acetyl urea, magnesium oxide
- Appearance
- A white, round, film-coated tablet.
01 / 03
1. Composition and Strength
1 tablet
- Active ingredient: Ibuprofen (KP)----75mg
Magnesium oxide (KP)----50mg
Caffeine Anhydrous (USP)----40mg
Allylisopropylacetylurea (KP)----30mg
- Additives (tar coloring): Blue No. 1
- Other additives: sodium lauryl sulfate, microcrystalline cellulose, magnesium stearate, low-substituted hydroxypropyl cellulose, croscarmellose sodium,
Polyethylene glycol 6000, hypromellose 2910
2. Effectiveness
1. Pain relief for headache, toothache, pain after tooth extraction, throat pain, ear pain, joint pain, neuralgia, back pain, muscle pain, shoulder pain, bruise pain, fracture pain, sprain pain, menstrual pain, and trauma pain.
2. Chills and fever relief
3. Dosage and dosage
Adults (15 years and older) take 2 tablets at a time, 3 times a day.
Avoid taking on an empty stomach and take the medication at least 4 hours apart.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk: The non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug may increase the risk of serious cardiovascular thrombotic (blood vessel blockage) reactions, myocardial infarction and stroke, which can be fatal. This risk may increase depending on the duration of administration. People with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Physicians and people must carefully monitor for the appearance of these cardiovascular symptoms, even if there is no history of cardiovascular disease. People should be aware of the signs and/or symptoms of serious cardiovascular toxicity and what measures to take if these symptoms appear.
Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischemic heart disease, peripheral artery disease, or cerebrovascular disease should use ibuprofen with careful consideration and avoid high-dose ibuprofen (2400 mg per day). Additionally, patients with cardiovascular risk factors (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking) who require high doses of ibuprofen (2400 mg per day) should be carefully considered before starting long-term treatment.
Clinical studies have shown that use of high doses (2400 mg per day) of ibuprofen may slightly increase the risk of arterial thrombosis (myocardial infarction or stroke). Overall, epidemiological studies have not demonstrated an association between low doses of ibuprofen (e.g., less than 1200 mg per day) and increased risk of arterial thrombotic events.
3) Gastrointestinal (intestinal) risk: Non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug may increase the risk of serious gastrointestinal (intestinal) adverse reactions, including bleeding, ulcers, and perforation of the stomach or intestinal tract (intestines), which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Elderly people may be at greater risk for serious gastrointestinal (intestinal) adverse reactions.
The longer the administration period, the more likely it is that serious gastrointestinal (intestinal) side effects will occur, but this risk cannot be completely ruled out during short-term administration.
While administering this drug, you should carefully monitor for symptoms and signs of gastrointestinal (intestinal) system ulcers or bleeding, and if severe (severe symptoms) adverse reactions in the gastrointestinal (intestinal) system are suspected, additional evaluation and treatment should be performed immediately. Discontinuation of this drug until severe (severe symptoms) adverse reactions in the gastrointestinal tract (intestines) are completely ruled out may be a treatment option. For people at high risk, alternative treatments unrelated to NSAIDs should be considered.
2. The following people should not take this medicine.
1) Peptic ulcer patients
2) Patients with severe blood abnormalities
3) Patients with hypersensitivity to the ingredients of this drug
4) Patients with bronchial asthma or a history of it
5) Patients with asthma, urticaria, allergic reactions or a history of such reactions to aspirin or other non-steroidal anti-inflammatory (anti-inflammatory) analgesics (including COX-2 inhibitors) (In these people, severe and fatal anaphylactoid reactions have been rarely reported after administration of non-steroidal anti-inflammatory (anti-inflammatory) analgesics.)
6) Treatment of pain occurring before and after coronary artery (heart artery) bypass surgery (CABG)
7) People who are pregnant or may be pregnant
8) People who are breastfeeding
3. Do not take the following medicines while taking this medicine.
1) When administered in combination with probenecid and sulfinpyrazone, this drug weakens the diuretic effect of probenecid and sulfinpyrazone, delaying the excretion of this drug.
2) When administered in combination with digoxin (taken together), the plasma concentration of digoxin increases.
3) When administered in combination with phenytoin (taken together), the plasma concentration of phenytoin increases.
4) Do not administer in combination (take together) with bacrofen because its toxicity is enhanced.
5) When administered in combination with diuretics or antihypertensive drugs (taken together), the effect is reduced.
6) ACE inhibitor (inhibitor): There are reports that the antihypertensive effect of ACE inhibitor (inhibitor) may be reduced by the non-steroidal anti-inflammatory (anti-inflammatory) analgesic contained in this drug, so this interaction should be kept in mind when administering this drug and ACE inhibitor (inhibitor) together (taken together).
7) Furosemide: Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some people due to this drug's inhibition of prostaglandin synthesis in the kidneys.
8) Aspirin
① There is no consistent evidence that combined use (taken together) with aspirin can reduce the risk of serious cardiovascular thrombotic (blood vessel blockage) reactions related to the use of non-steroidal anti-inflammatory (anti-inflammatory) painkillers contained in this drug. As with other non-steroidal anti-inflammatory (anti-inflammatory) analgesics, the risk of severe (severe symptoms) adverse reactions in the gastrointestinal tract (intestines) may increase due to the combined use of this drug and aspirin.
② When administered in combination with aspirin (taken together), the action of this drug and other non-steroidal anti-inflammatory (anti-inflammatory) analgesics may be reduced.
9) Lithium: The non-steroidal anti-inflammatory (anti-inflammatory) analgesic contained in this drug may increase serum lithium concentration and decrease renal clearance of lithium by inhibiting prostaglandin synthesis in the kidneys. Therefore, when coadministering nonsteroidal anti-inflammatory (anti-inflammatory) analgesics and lithium together, signs of lithium toxicity must be carefully observed.
10) Methotrexate: Because the hematological toxicity of methotrexate increases with concurrent administration (taken together) with the non-steroidal anti-inflammatory (anti-inflammatory) analgesic contained in this drug, the two drugs should not be administered (taken together) together.
11) Oral anticoagulants (blood coagulation inhibitors) (warfarin, etc.)
① Regarding gastrointestinal (intestinal) bleeding, warfarin and the non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug may have a synergistic effect, so people who use both drugs together may have an increased risk of severe (severe symptoms) gastrointestinal (intestinal) bleeding compared to those who take the two drugs alone.
② When administered in combination with oral anticoagulants (blood coagulation inhibitors), its action may be enhanced.
12) Other antipyretic analgesics, cold medicines, sedatives, motion sickness medicines
4. Do not do the following while taking this medicine.
1) This drug has been reported to pass into breast milk, and there is concern that serious adverse reactions may occur in infants (newborns) due to this, so this drug should not be taken while breastfeeding or while breastfeeding.
2) While taking this medicine, you may feel drowsy, so avoid driving a car or operating machinery.
3) Avoid drinking alcohol while taking this medicine.
4) Do not use for a long period of time (continuously taking it).
5. The following people should consult a doctor, dentist, or pharmacist before taking this medicine.
1) Patients with a history of peptic ulcer
2) Patients with hepatic impairment or its history
3) Patients with renal impairment (kidney dysfunction) or a history of it
4) Patients with cardiac dysfunction
5) Patients with systemic lupus erythematosus syndrome and mixed connective tissue disease
6) Senior citizens (elderly)
7) Patients taking probenecid, sulfinpyrazone, digoxin, phenytoin, diuretics, antihypertensive drugs, ACE inhibitors (inhibitors), furosemide, lithium, oral anticoagulants (blood coagulants)
8) People taking low-dose aspirin for the purpose of preventing myocardial infarction or stroke (This drug may reduce the effectiveness of aspirin and increase the risk of serious gastrointestinal adverse reactions.)
Laboratory data have shown that ibuprofen can inhibit the platelet aggregation effect of low-dose aspirin when administered in combination with ibuprofen and aspirin (acetylsalicylic acid). Although clinical uncertainty exists regarding the extrapolation of these data, regular or long-term ibuprofen use may reduce the cardioprotective effects of low-dose aspirin.
6. In the following cases, stop taking this medicine immediately and consult a doctor, dentist, or pharmacist. Please carry this attached document with you whenever possible during the consultation.
1) Digestive system: Symptoms such as nausea, abdominal distension, stomach pain, heartburn, loss of appetite, diarrhea, constipation, vomiting, gastritis, latent excessive bleeding, and stomatitis (mouth inflammation) may occur. In addition, in rare cases, symptoms of digestive system ulcers accompanied by bleeding may appear.
2) Nervous system: Occasionally, symptoms such as central nervous system adverse reactions such as inhibition of reactivity, headache, depression, dizziness, insomnia, fear, and impaired consciousness may appear. Additionally, in rare cases, nervous seizures may occur. In rare cases, aseptic meningitis may occur in patients with autoimmune disease (systemic lupus erythematosus syndrome).
3) Sensory system: Occasionally symptoms such as tinnitus (ringing in the ears), hearing loss (deafness), and amblyopia may appear.
4) Hypersensitivity: In rare cases, urticaria, purpura (purple spots), itching, and rash may occur. In such cases, discontinue administration.
5) Skin: In very rare cases, Stevens-Johnson syndrome (cutaneous muco-ocular syndrome), photosensitivity reaction (frequency unknown), erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis, and drug rash accompanied by unknown eosinophilia and systemic syndrome (DRESS syndrome) and acute generalized erythroderma pustulosis (AGEP) may occur. In these cases, discontinue use.
6) Liver: In rare cases, jaundice and elevation of GOT, GPT, and AL-P may occur.
7) Blood: In rare cases, aplastic anemia, hemolytic anemia, autoimmune hemorrhagic anemia, bleeding, decreased granulocytosis, decreased platelet function, decreased platelet function (prolonged bleeding time), etc. may occur. Therefore, conduct sufficient observation, including blood tests, and immediately discontinue administration if any abnormalities occur.
8) Kidney (kidney): In rare cases, it may cause acute renal failure, so if symptoms such as oliguria (reduced urination), hematuria, elevated urine protein, BUN, or blood creatinine, or hyperkalemia appear in the test results, discontinue administration and take appropriate measures. Whole body edema (swelling) may occur.
9) Overdosage of this drug may cause metabolic acidosis.
7. Other precautions when taking this drug
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. This drug is administered at the lowest effective dose for the shortest possible period to match each person's treatment goals.
2) Adverse reactions in the gastrointestinal tract (intestines): Extreme caution should be exercised when prescribing the non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug to people with a history of ulcerative disease or gastrointestinal (intestinal) bleeding. In people with a history of peptic ulcer disease and/or gastrointestinal (intestinal) bleeding, the risk of developing gastrointestinal (intestinal) bleeding increases more than 10 times when taking non-steroidal anti-inflammatory (NSAID) analgesics compared to people without these risk factors. Other risk factors that increase gastrointestinal (intestinal) bleeding include concurrent use of oral corticosteroids or anticoagulants, long-term use of nonsteroidal anti-inflammatory painkillers, alcohol consumption, old age, and poor health. Most of the spontaneous reports of fatal gastrointestinal (intestinal) adverse reactions are in elderly and frail people, so special caution should be exercised when administering this drug to these people.
3) High blood pressure: Non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug may cause high blood pressure or worsen existing high blood pressure, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have a decreased response to these therapies when taking nonsteroidal anti-inflammatory (anti-inflammatory) painkillers. The non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug should be administered with caution in patients with high blood pressure. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
4) Congestive heart failure and edema (swelling): Fluid retention and edema (swelling) have been observed in some people taking non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug. This drug should be administered with caution in patients with fluid retention or heart failure.
5) If you take the non-steroidal anti-inflammatory (anti-inflammatory) painkillers contained in this medicine for a long time, kidney papillary necrosis or other kidney damage may occur. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients with heart failure, patients with renal dysfunction, patients with liver dysfunction (loss of liver function), patients taking diuretics or ACE inhibitors (inhibitors), and the elderly (elderly). When medication is stopped, most cases return to their pre-treatment state.
6) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
7) Administration of non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, severe liver-related adverse reactions, including jaundice, fatal fulminant hepatitis (rapidly developing hepatitis), liver necrosis, and liver failure (loss of liver function) (some of which are fatal), have been rarely reported due to administration of the non-steroidal anti-inflammatory analgesic contained in this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs (e.g. eosinophilia, rash) related to liver disease appear (e.g., eosinophilia, rash), administration of this drug should be discontinued.
8) Since anemia may occur due to administration of the non-steroidal anti-inflammatory analgesic contained in this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
The non-steroidal anti-inflammatory (anti-inflammatory) analgesic contained in this drug inhibits platelet aggregation and has been confirmed to prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants, should be carefully monitored when receiving this drug.
9) Patients taking the non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug for a long period of time should regularly perform a complete blood count (CBC) and physicochemical tests.
If clinical symptoms or systemic signs (e.g., eosinophilia, rash) associated with liver or renal disease develop (e.g., eosinophilia, rash), or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
10) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory (anti-inflammatory) analgesics, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who develop severe, potentially fatal, bronchospasm with or without nasal polyps after taking aspirin or other NSAIDs. If such an anaphylactoid reaction occurs, emergency treatment must be administered.
11) Skin reactions: This drug may cause severe skin adverse reactions (including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, erythema multiforme, DRESS syndrome and acute generalized erythroderma pustulosis (AGEP)), which may be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin manifestations and signs and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
12) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. In these aspirin-sensitive patients, cross-reactivity, including bronchospasm, has been reported between aspirin and other non-steroidal anti-inflammatory (NSAID) analgesics. Therefore, this drug should not be administered to aspirin-sensitive patients.
13) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroid administration may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
14) Due to the pharmacological properties of this drug, it may delay the diagnosis of infectious complications under painful and non-infectious conditions by suppressing fever and other symptoms and signs of inflammation.
15) If symptoms do not improve even after taking it several times, stop taking it and consult a doctor or pharmacist.
8. Storage precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
3) Avoid direct sunlight, if possible, and store in a cool, low-humidity place.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
10 tablets/PTP
7. Period of use
36 months from date of manufacture
1 tablet
- Active ingredient: Ibuprofen (KP)----75mg
Magnesium oxide (KP)----50mg
Caffeine Anhydrous (USP)----40mg
Allylisopropylacetylurea (KP)----30mg
- Additives (tar coloring): Blue No. 1
- Other additives: sodium lauryl sulfate, microcrystalline cellulose, magnesium stearate, low-substituted hydroxypropyl cellulose, croscarmellose sodium,
Polyethylene glycol 6000, hypromellose 2910
2. Effectiveness
1. Pain relief for headache, toothache, pain after tooth extraction, throat pain, ear pain, joint pain, neuralgia, back pain, muscle pain, shoulder pain, bruise pain, fracture pain, sprain pain, menstrual pain, and trauma pain.
2. Chills and fever relief
3. Dosage and dosage
Adults (15 years and older) take 2 tablets at a time, 3 times a day.
Avoid taking on an empty stomach and take the medication at least 4 hours apart.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk: The non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug may increase the risk of serious cardiovascular thrombotic (blood vessel blockage) reactions, myocardial infarction and stroke, which can be fatal. This risk may increase depending on the duration of administration. People with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Physicians and people must carefully monitor for the appearance of these cardiovascular symptoms, even if there is no history of cardiovascular disease. People should be aware of the signs and/or symptoms of serious cardiovascular toxicity and what measures to take if these symptoms appear.
Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischemic heart disease, peripheral artery disease, or cerebrovascular disease should use ibuprofen with careful consideration and avoid high-dose ibuprofen (2400 mg per day). Additionally, patients with cardiovascular risk factors (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking) who require high doses of ibuprofen (2400 mg per day) should be carefully considered before starting long-term treatment.
Clinical studies have shown that use of high doses (2400 mg per day) of ibuprofen may slightly increase the risk of arterial thrombosis (myocardial infarction or stroke). Overall, epidemiological studies have not demonstrated an association between low doses of ibuprofen (e.g., less than 1200 mg per day) and increased risk of arterial thrombotic events.
3) Gastrointestinal (intestinal) risk: Non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug may increase the risk of serious gastrointestinal (intestinal) adverse reactions, including bleeding, ulcers, and perforation of the stomach or intestinal tract (intestines), which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Elderly people may be at greater risk for serious gastrointestinal (intestinal) adverse reactions.
The longer the administration period, the more likely it is that serious gastrointestinal (intestinal) side effects will occur, but this risk cannot be completely ruled out during short-term administration.
While administering this drug, you should carefully monitor for symptoms and signs of gastrointestinal (intestinal) system ulcers or bleeding, and if severe (severe symptoms) adverse reactions in the gastrointestinal (intestinal) system are suspected, additional evaluation and treatment should be performed immediately. Discontinuation of this drug until severe (severe symptoms) adverse reactions in the gastrointestinal tract (intestines) are completely ruled out may be a treatment option. For people at high risk, alternative treatments unrelated to NSAIDs should be considered.
2. The following people should not take this medicine.
1) Peptic ulcer patients
2) Patients with severe blood abnormalities
3) Patients with hypersensitivity to the ingredients of this drug
4) Patients with bronchial asthma or a history of it
5) Patients with asthma, urticaria, allergic reactions or a history of such reactions to aspirin or other non-steroidal anti-inflammatory (anti-inflammatory) analgesics (including COX-2 inhibitors) (In these people, severe and fatal anaphylactoid reactions have been rarely reported after administration of non-steroidal anti-inflammatory (anti-inflammatory) analgesics.)
6) Treatment of pain occurring before and after coronary artery (heart artery) bypass surgery (CABG)
7) People who are pregnant or may be pregnant
8) People who are breastfeeding
3. Do not take the following medicines while taking this medicine.
1) When administered in combination with probenecid and sulfinpyrazone, this drug weakens the diuretic effect of probenecid and sulfinpyrazone, delaying the excretion of this drug.
2) When administered in combination with digoxin (taken together), the plasma concentration of digoxin increases.
3) When administered in combination with phenytoin (taken together), the plasma concentration of phenytoin increases.
4) Do not administer in combination (take together) with bacrofen because its toxicity is enhanced.
5) When administered in combination with diuretics or antihypertensive drugs (taken together), the effect is reduced.
6) ACE inhibitor (inhibitor): There are reports that the antihypertensive effect of ACE inhibitor (inhibitor) may be reduced by the non-steroidal anti-inflammatory (anti-inflammatory) analgesic contained in this drug, so this interaction should be kept in mind when administering this drug and ACE inhibitor (inhibitor) together (taken together).
7) Furosemide: Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some people due to this drug's inhibition of prostaglandin synthesis in the kidneys.
8) Aspirin
① There is no consistent evidence that combined use (taken together) with aspirin can reduce the risk of serious cardiovascular thrombotic (blood vessel blockage) reactions related to the use of non-steroidal anti-inflammatory (anti-inflammatory) painkillers contained in this drug. As with other non-steroidal anti-inflammatory (anti-inflammatory) analgesics, the risk of severe (severe symptoms) adverse reactions in the gastrointestinal tract (intestines) may increase due to the combined use of this drug and aspirin.
② When administered in combination with aspirin (taken together), the action of this drug and other non-steroidal anti-inflammatory (anti-inflammatory) analgesics may be reduced.
9) Lithium: The non-steroidal anti-inflammatory (anti-inflammatory) analgesic contained in this drug may increase serum lithium concentration and decrease renal clearance of lithium by inhibiting prostaglandin synthesis in the kidneys. Therefore, when coadministering nonsteroidal anti-inflammatory (anti-inflammatory) analgesics and lithium together, signs of lithium toxicity must be carefully observed.
10) Methotrexate: Because the hematological toxicity of methotrexate increases with concurrent administration (taken together) with the non-steroidal anti-inflammatory (anti-inflammatory) analgesic contained in this drug, the two drugs should not be administered (taken together) together.
11) Oral anticoagulants (blood coagulation inhibitors) (warfarin, etc.)
① Regarding gastrointestinal (intestinal) bleeding, warfarin and the non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug may have a synergistic effect, so people who use both drugs together may have an increased risk of severe (severe symptoms) gastrointestinal (intestinal) bleeding compared to those who take the two drugs alone.
② When administered in combination with oral anticoagulants (blood coagulation inhibitors), its action may be enhanced.
12) Other antipyretic analgesics, cold medicines, sedatives, motion sickness medicines
4. Do not do the following while taking this medicine.
1) This drug has been reported to pass into breast milk, and there is concern that serious adverse reactions may occur in infants (newborns) due to this, so this drug should not be taken while breastfeeding or while breastfeeding.
2) While taking this medicine, you may feel drowsy, so avoid driving a car or operating machinery.
3) Avoid drinking alcohol while taking this medicine.
4) Do not use for a long period of time (continuously taking it).
5. The following people should consult a doctor, dentist, or pharmacist before taking this medicine.
1) Patients with a history of peptic ulcer
2) Patients with hepatic impairment or its history
3) Patients with renal impairment (kidney dysfunction) or a history of it
4) Patients with cardiac dysfunction
5) Patients with systemic lupus erythematosus syndrome and mixed connective tissue disease
6) Senior citizens (elderly)
7) Patients taking probenecid, sulfinpyrazone, digoxin, phenytoin, diuretics, antihypertensive drugs, ACE inhibitors (inhibitors), furosemide, lithium, oral anticoagulants (blood coagulants)
8) People taking low-dose aspirin for the purpose of preventing myocardial infarction or stroke (This drug may reduce the effectiveness of aspirin and increase the risk of serious gastrointestinal adverse reactions.)
Laboratory data have shown that ibuprofen can inhibit the platelet aggregation effect of low-dose aspirin when administered in combination with ibuprofen and aspirin (acetylsalicylic acid). Although clinical uncertainty exists regarding the extrapolation of these data, regular or long-term ibuprofen use may reduce the cardioprotective effects of low-dose aspirin.
6. In the following cases, stop taking this medicine immediately and consult a doctor, dentist, or pharmacist. Please carry this attached document with you whenever possible during the consultation.
1) Digestive system: Symptoms such as nausea, abdominal distension, stomach pain, heartburn, loss of appetite, diarrhea, constipation, vomiting, gastritis, latent excessive bleeding, and stomatitis (mouth inflammation) may occur. In addition, in rare cases, symptoms of digestive system ulcers accompanied by bleeding may appear.
2) Nervous system: Occasionally, symptoms such as central nervous system adverse reactions such as inhibition of reactivity, headache, depression, dizziness, insomnia, fear, and impaired consciousness may appear. Additionally, in rare cases, nervous seizures may occur. In rare cases, aseptic meningitis may occur in patients with autoimmune disease (systemic lupus erythematosus syndrome).
3) Sensory system: Occasionally symptoms such as tinnitus (ringing in the ears), hearing loss (deafness), and amblyopia may appear.
4) Hypersensitivity: In rare cases, urticaria, purpura (purple spots), itching, and rash may occur. In such cases, discontinue administration.
5) Skin: In very rare cases, Stevens-Johnson syndrome (cutaneous muco-ocular syndrome), photosensitivity reaction (frequency unknown), erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis, and drug rash accompanied by unknown eosinophilia and systemic syndrome (DRESS syndrome) and acute generalized erythroderma pustulosis (AGEP) may occur. In these cases, discontinue use.
6) Liver: In rare cases, jaundice and elevation of GOT, GPT, and AL-P may occur.
7) Blood: In rare cases, aplastic anemia, hemolytic anemia, autoimmune hemorrhagic anemia, bleeding, decreased granulocytosis, decreased platelet function, decreased platelet function (prolonged bleeding time), etc. may occur. Therefore, conduct sufficient observation, including blood tests, and immediately discontinue administration if any abnormalities occur.
8) Kidney (kidney): In rare cases, it may cause acute renal failure, so if symptoms such as oliguria (reduced urination), hematuria, elevated urine protein, BUN, or blood creatinine, or hyperkalemia appear in the test results, discontinue administration and take appropriate measures. Whole body edema (swelling) may occur.
9) Overdosage of this drug may cause metabolic acidosis.
7. Other precautions when taking this drug
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. This drug is administered at the lowest effective dose for the shortest possible period to match each person's treatment goals.
2) Adverse reactions in the gastrointestinal tract (intestines): Extreme caution should be exercised when prescribing the non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug to people with a history of ulcerative disease or gastrointestinal (intestinal) bleeding. In people with a history of peptic ulcer disease and/or gastrointestinal (intestinal) bleeding, the risk of developing gastrointestinal (intestinal) bleeding increases more than 10 times when taking non-steroidal anti-inflammatory (NSAID) analgesics compared to people without these risk factors. Other risk factors that increase gastrointestinal (intestinal) bleeding include concurrent use of oral corticosteroids or anticoagulants, long-term use of nonsteroidal anti-inflammatory painkillers, alcohol consumption, old age, and poor health. Most of the spontaneous reports of fatal gastrointestinal (intestinal) adverse reactions are in elderly and frail people, so special caution should be exercised when administering this drug to these people.
3) High blood pressure: Non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug may cause high blood pressure or worsen existing high blood pressure, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have a decreased response to these therapies when taking nonsteroidal anti-inflammatory (anti-inflammatory) painkillers. The non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug should be administered with caution in patients with high blood pressure. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
4) Congestive heart failure and edema (swelling): Fluid retention and edema (swelling) have been observed in some people taking non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug. This drug should be administered with caution in patients with fluid retention or heart failure.
5) If you take the non-steroidal anti-inflammatory (anti-inflammatory) painkillers contained in this medicine for a long time, kidney papillary necrosis or other kidney damage may occur. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients with heart failure, patients with renal dysfunction, patients with liver dysfunction (loss of liver function), patients taking diuretics or ACE inhibitors (inhibitors), and the elderly (elderly). When medication is stopped, most cases return to their pre-treatment state.
6) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
7) Administration of non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, severe liver-related adverse reactions, including jaundice, fatal fulminant hepatitis (rapidly developing hepatitis), liver necrosis, and liver failure (loss of liver function) (some of which are fatal), have been rarely reported due to administration of the non-steroidal anti-inflammatory analgesic contained in this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs (e.g. eosinophilia, rash) related to liver disease appear (e.g., eosinophilia, rash), administration of this drug should be discontinued.
8) Since anemia may occur due to administration of the non-steroidal anti-inflammatory analgesic contained in this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
The non-steroidal anti-inflammatory (anti-inflammatory) analgesic contained in this drug inhibits platelet aggregation and has been confirmed to prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants, should be carefully monitored when receiving this drug.
9) Patients taking the non-steroidal anti-inflammatory (anti-inflammatory) analgesics contained in this drug for a long period of time should regularly perform a complete blood count (CBC) and physicochemical tests.
If clinical symptoms or systemic signs (e.g., eosinophilia, rash) associated with liver or renal disease develop (e.g., eosinophilia, rash), or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
10) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory (anti-inflammatory) analgesics, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who develop severe, potentially fatal, bronchospasm with or without nasal polyps after taking aspirin or other NSAIDs. If such an anaphylactoid reaction occurs, emergency treatment must be administered.
11) Skin reactions: This drug may cause severe skin adverse reactions (including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, erythema multiforme, DRESS syndrome and acute generalized erythroderma pustulosis (AGEP)), which may be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin manifestations and signs and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
12) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. In these aspirin-sensitive patients, cross-reactivity, including bronchospasm, has been reported between aspirin and other non-steroidal anti-inflammatory (NSAID) analgesics. Therefore, this drug should not be administered to aspirin-sensitive patients.
13) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroid administration may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
14) Due to the pharmacological properties of this drug, it may delay the diagnosis of infectious complications under painful and non-infectious conditions by suppressing fever and other symptoms and signs of inflammation.
15) If symptoms do not improve even after taking it several times, stop taking it and consult a doctor or pharmacist.
8. Storage precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
3) Avoid direct sunlight, if possible, and store in a cool, low-humidity place.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
10 tablets/PTP
7. Period of use
36 months from date of manufacture
Product Updates
Total 1items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 1 | GnalN-Q Tab. | Precautions for use | 2024.07.15 | PDFThat day NQjeong_Change plan + Change comparison table.pdf |